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We recently reported the synthesis of NOSH-aspirin, a novel hybrid that releases both nitric oxide (NO)
and hydrogen sulﬁde (H2S). In NOSH-aspirin, the two moieties that release NO and H2S are covalently
linked at the 1, 2 positions of acetyl salicylic acid, i.e. ortho-NOSH-aspirin (o-NOSH-aspirin). In the present
study, we compared the effects of the positional isomers of NOSH-ASA (o-NOSH-aspirin, m-NOSH-aspirin
and p-NOSH-aspirin) to that of aspirin on growth of HT-29 and HCT 15 colon cancer cells, belonging to the
same histological subtype, but with different expression of cyclooxygenase (COX) enzymes; HT-29 express
both COX-1 and COX-2, whereas HCT 15 is COX-null. We also analyzed the effect of these compounds on
proliferation and apoptosis in HT-29 cells. Since the parent compound aspirin, inhibits both COX-1 and
COX-2, we also evaluated the effects of these compounds on COX-1 and COX-2 enzyme activities and also
performed modeling of the interactions between the positional isomers of NOSH-aspirin and COX-1 and
COX-2 enzymes. We observed that the three positional isomers of NOSH aspirin inhibited the growth of
both colon cancer cell lines with IC50s in the nano-molar range. In particular in HT-29 cells the IC50s for
growth inhibition were: o-NOSH-ASA, 0.04 70.011 mM; m-NOSH-ASA, 0.2470.11 mM; p-NOSH-ASA,
0.4670.17 mM; and in HCT 15 cells the IC50s for o-NOSH-ASA, m-NOSH-ASA, and p-NOSH-ASA were 0.062
70.006 mM, 0.09270.004 mM, and 0.3770.04 mM, respectively. The IC50 for aspirin in both cell lines was
45 mM at 24 h. The reduction of cell growth appeared to be mediated through inhibition of proliferation,
and induction of apoptosis. All 3 positional isomers of NOSH-aspirin preferentially inhibited COX-1 over
COX-2. These results suggest that the three positional isomers of NOSH-aspirin have the same biological
actions, but that o-NOSH-ASA displayed the strongest anti-neoplastic potential.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Non-steroidal anti-inﬂammatory drugs (NSAIDs) in general and
aspirin in particular have anti-cancer activities [1–3]. Unfortunately, prolonged use of these agents may lead to potentially
life threatening side effects; including renal, cardiovascular, and
gastrointestinal, reviewed in [4]. In our efforts to develop a safer
aspirin, we synthesized NOSH-aspirin [5], a hybrid molecule that
releases nitric oxide (NO) and hydrogen sulﬁde (H2S), two gasotransmitters of physiological importance [6]. The development of
☆
This article belongs to a special issue on Nitric Oxide and Cancer, edited by Jordi
Muntané and Benjamin Bonavida.
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NOSH-aspirin was based on the observation that NO [7–9] and H2S
[10–12] have some of the same general properties as prostaglandins (PGs) within gastric mucosa and that should compensate for the reduced gastric PGs caused by aspirin, thus enhancing
the local mucosal defense systems.
NOSH-aspirin has been shown to have strong anti-inﬂammatory properties; have IC50s for cell growth inhibition in the
nano-molar range in 11 different human cancer cell lines of six
different tissue origins (colon, breast, pancreas, lung, prostate and
leukemia) [5]. Although highly potent, NOSH-aspirin was shown to
have very limited cyto-toxicity as demonstrated by the very low
(o10%) lactate dehydrogenase (LDH) release at four times its IC50
for cell growth inhibition at 24 h [5]. It was also shown to have
superior gastrointestinal safety proﬁle compared to aspirin [13]
and was very efﬁcacious in an in vivo model of human colon cancer
xenografts in mice [14].

http://dx.doi.org/10.1016/j.redox.2015.08.014
2213-2317/& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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In the present study we compared the cell growth inhibitory
properties of o-NOSH-aspirin (in which the two moieties that release NO and H2S are covalently linked at the 1, 2 positions of
acetyl salicylic acid) to that of the 1, 3 (m-NOSH-aspirin) and the 1,
4 (p-NOSH-aspirin) positional isomers on HT-29 and HCT-15 colon
cancer cell lines. We also veriﬁed the potential anti-growth activity of the positional isomers of NOSH-ASA on HT-29 colon
cancer cell proliferation, and apoptosis. The effect of these agents
on COX-1 and COX-2 enzymatic activity were also evaluated together with molecular modeling studies to determine their binding interactions with these enzymes.
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immobilized onto the surface of microtiter wells provided in the
kit. HT-29 cancer cells containing antigen in suspension buffer
(5 mM EDTA, 0.2 mM phenylmethyl sulfonyl ﬂuoride, 1 mg/mL
pepstatin, 0.5 mg/mL leupeptin and 50 mM Tris/HCl pH 8.0) were
pipetted into the wells followed by incubation with biotinylated
detector monoclonal antibody (clone PC10) for 2 h. Unbound
material was washed away and horseradish peroxidase-conjugated streptavidin was added and incubated for 30 min at room
temperature. After another 30 min of incubation with the chromogenic substrate TetraMethylBenzidine (TMB) and the addiction
of the stop solution, the colored reaction product was quantiﬁed
using a spectrophotometer. The absorbance of the solutions in the
wells was measured at 450 nm.

2. Materials and methods
2.5. Assay for apoptosis
2.1. Reagents
NOSH-aspirin, 4-(3-thioxo-3H-1,2-dithiol-5-yl)phenyl 2-((4(nitrooxy)butanoyl)oxy)benzoate (o-NOSH-ASA), and the positional isomers, [4-(3-thioxo-3H-1,2-dithiol-5-yl)phenyl 4-((4-(nitrooxy)butanoyl)oxy)benzoate] (p-NOSH-ASA) and [4-(3-thioxo3H-1,2-dithiol-5-yl)phenyl 3-((4-(nitrooxy)butanoyl)oxy)benzoate] (m-NOSH-ASA), were synthesized as described [15] and were
gifts from Avicenna Pharmaceuticals Inc (New York, NY). Stock
(100 mM) solutions of the test compounds were prepared in dimethyl sulfoxide (Fisher Scientiﬁc, Fair Lawn, NJ). Traditional aspirin was obtained from Sigma-Aldrich (St. Louis, MO).
2.2. Cell culture
HT-29 (ATCCs HTB38™) and HCT-15 (ATCCs CCL-221™) human colon adenocarcinoma were obtained from American Type
Tissue Collection (Manassas, VA). HT-29 cells express both COX-1
(cyclo-oxygenase) and COX-2 enzymes, instead HCT-15 cells are
COX null [16]. HT-29 and HCT-15 human colon cancer cells were
grown as monolayer in McCoy 5A and RPMI-1640 media, respectively. All media were supplemented with 10% fetal bovine serum
(Invitrogen, Carlsbad, CA), 1% penicillin (50 U/ml) and streptomycin (50 mg/ml) (Invitrogen, Carlsbad, CA). Cells were seeded on
culture dishes making a 1:5 dilution and incubated at 37 °C in 5%
CO2 and 90% relative humidity. Single cell suspensions were obtained by trypsinization (0.05% trypsin/EDTA) and cells were
counted using a hemocytometer. For cryopreservation of the
complete growth media, the ﬁnal DMSO (dimethyl sulfoxide)
concentration was adjusted to 1%.
2.3. Cell growth inhibition
Cell growth inhibitory effect of the positional isomers of NOSHaspirin was measured using a colorimetric MTT assay kit (Roche,
Indianapolis, IN).
HT-29 and HCT-15 cancer cells were plated in 96-well plates at
a density of 30,000 cells/well. The cells were incubated for 24 h
with different concentrations of positional isomers of NOSH-ASA.
The absorbance of the plates was measured on a spectrophotometric plate reader at a wavelength of 570 nm.
2.4. Assay for cell proliferation
The levels of proliferating cell nuclear antigen (PCNA) was determined using an ELISA (enzyme-linked immunosorbent assay)
Kit (Calbiochem, La Jolla, CA), in accordance with the manufacturers protocol. The HT-29 cells (1  106 cells/mL) were treated
for 24 h with different multiples of IC50s for cell growth inhibition
of each of the positional isomers of NOSH-aspirin. A polyclonal
antibody, speciﬁc for the human PCNA protein, has been

HT-29 cells (1  106 cells/mL) were treated with the positional
isomers of NOSH-aspirin at their respective IC50 for cell growth
inhibition for 24 h. Cells were washed and resuspended in 500 mL
of 1X Binding Buffer (Annexin V binding buffer, 0.1 M HEPES/NaOH
(pH 7.4), 1.4 M NaCl, 25 mM CaCl2; BD BioSciences Pharmingen,
San Diego, CA). Then, 10 mL of Annexin V-FITC (ﬁnal concentration:
0.5 mg/mL) was added to the FACS tube followed by 10 mL of
Propidium Iodide (PI). After 20 min of incubation in the dark at
room temperature, percentage of apoptotic cells was measured by
ﬂow cytometry using a Becton Dickinson LSR II equipped with a
single argon ion laser. Thus, cells that are considered viable are
both Annexin V and PI negative, while cells that are in early
apoptosis are Annexin V positive and PI negative, cells that are in
late apoptosis are both Annexin V and PI positive and cells already
dead are Annexin V negative and PI positive. For each subset,
about 10,000 events were analyzed. All the parameters were collected in list mode ﬁles, and the data were analyzed by Flow Jo
software.
2.6. Cyclooxygenase inhibition assay
Ovine COX-1 or COX-2 (200 units) were incubated in the presence of the positional isomers of NOSH-aspirin at their respective
IC50s for cell growth inhibition, in 600 mL of reaction buffer
(100 mM) Tris-maleate buffer, pH 6.5, 0.1% Tween-20, gelatin at
(1 mg/mL), hematin (3 mM), and TMPD (100 mM, Sigma-Aldrich, St.
Louis, MO). The concentration of DMSO was always 10% of the ﬁnal
volume. After incubating the samples for 30 min at 4 °C, arachidonic acid (100 mM) was added to start the enzymatic reaction,
this was incubated for 5 min at 25 °C. The COX enzymes activity
was measured by monitoring the oxidation of TMPD at 600 nm in
a microtiter plate. The percent inhibition was determined as previously reported [17]. We also measured the degree of COX-1 and
COX-2 inhibition by conventional aspirin (1 mM) and indomethacin (1 mM) as reference compound.
2.7. Molecular docking experiments
Docking experiments were performed using the computational
software Discovery Studio (DS) Client version 4.0, Structure-BasedDesign from Accelrys/BIOVIA Inc., San Diego, USA Software Inc. The
NOSH-aspirin derivatives were constructed using the small molecules module in DS and were energy minimized by 1000 steps
each of steepest descent followed by conjugate gradient minimization using a distance dependent dielectric constant and
CHARMm force ﬁeld. The x-ray crystal structure of the COX inhibitor meloxicam bound to COX-1 enzyme was obtained from
protein data bank (pdb id: 4O1Z) [18]. The enzyme was prepared
for docking studies using the macromolecules module in DS. The
COX-1 active site was deﬁned by selecting a sphere of 15 Å radius
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around meloxicam after which meloxicam was deleted. The
NOSH-aspirin derivatives were docked using the ligand–receptor
interactions module in DS. The CDOCKER protocol was used to
conduct docking studies. It is based on a simulated annealing
principle which generates ten top ligand binding poses. These are
ranked based on CDOCKER energy and CDOCKER interaction energy in kcal/mol. The best pose obtained is further analyzed by
considering the number and types of polar and nonpolar interactions with the COX-1 enzyme. It should be noted that the molecular docking experiment was conducted by considering an implicit-water function Generalized-Born with Switching Function
(GBSW), present in DS, to account for the effect of hydrophilic
environment on enzyme–ligand complex. A similar docking study
of NOSH-aspirin derivatives with COX-2 enzyme was carried out
by using the x-ray crystal structure of isoxicam bound to COX-2
enzyme (pdb id: 4M10) [18].
2.8. Statistical analysis
Data are presented as means 7 SEM for at least 3–5 different
sets of plates and treatment groups. Statistical comparison among
the groups was performed using Student's t-test, P-values o0.05
were considered signiﬁcant.

3. Results and discussion
3.1. Positional isomers of NOSH-aspirin are potent inhibitors of HT29 and HCT 15 human colon cancer cell growth
The structural components of the three positional isomers of
NOSH-aspirin are shown in Fig. 1. HT-29 and HCT 15 cells were
treated with various concentrations of aspirin, o-NOSH-ASA, mNOSH-ASA, and p-NOSH-ASA for 24 h and compared with vehicle
treated controls. As shown in Fig. 2, all three positional isomers of
NOSH-ASA strongly inhibited the growth of the HT-29 cells in a
concentration dependent manner. Similar dose–response curves
were obtained for HCT 15 cells (data not shown). From such dose–
response curves, IC50s for cell growth inhibition were determined
and are presented in Table 1. The IC50 for the parent compound
aspirin, in both cell lines was greater than 5 mM whereas the IC50s
for the positional isomers of NOSH-ASA was in the nano-molar
range. Speciﬁcally, the IC50s in HT-29 cells were: o-NOSH-ASA
(40 711 nM), m-NOSH-ASA (240 7110 nM) and p-NOSH-ASA
(460 7170 nM). This represents an enhanced potency of
410,000-fold for p-NOSH-ASA, 420,000-fold for m-NOSH-ASA,
and 4125,000-fold for o-NOSH-ASA. Similarly, the IC50s in HCT 15
cells were: o-NOSH-ASA (627 6 nM), m-NOSH-ASA (92 74 nM)

Fig. 2. Inhibitory effects of o-, m-, p-NOSH-ASA on HT-29 cell growth. Cells were
treated with various concentrations of o-, m-, p-NOSH-ASA as described in Section
2.3. Cell viability was determined by MTT at 24 h.

Table 1
IC50 values at 24 h for cell growth inhibition in HT-29 and HCT 15 human colon
cancer cell lines.
Origin/Cell line, IC50 (nM)
Compound

Colon, HT-29

Colon, HCT 15

Aspirin
o-NOSH-aspirin
Enhanced potency
m-NOSH-aspirin
Enhanced potency
p-NOSH-aspirin
Enhanced potency

4 5,000,000
407 11
4 125,000
2407 110
4 20,000
460 7 170
4 10,000

45,000,000
627 6
480,000
927 4
450,000
3707 40
413,000

HT-29 (COX-1/ -2 positive) and HCT 15 (COX null) human colon cancer cell lines were
treated with various concentrations of the positional isomers of NOSH-ASA as described under Section 2.3. Cell numbers were determined at 24 h from which IC50
values were calculated. Results are mean7S.E.M. of ﬁve different experiments done in
triplicate. For HT-29 cells, signiﬁcance between the treatment groups were: o vs m,
P40.05; o vs p, Po0.05; m vs p, P40.05. For HCT 15 cells, signiﬁcance between the
treatment groups were: o vs m, Po0.01; o vs p, Po0.001; m vs p, Po0.001.

and p-NOSH-ASA (370740 nM). This represents an enhanced
potency of 413,000-fold for p-NOSH-ASA, 450,000-fold for
m-NOSH-ASA, and 480,000-fold for o-NOSH-ASA. This enhanced

Fig. 1. The chemical structures of the positional isomers of NOSH-aspirin. The three structural components NOSH-ASA are indicated. H2S is released from degradation of the
ADT-OH (5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione) moiety and NO is released from the nitrate group, both shown in the dotted ellipses, respectively. The parent
compound, aspirin is shown in the shaded box.
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potency of the positional isomer of NOSH-ASA compared to the
parent compound ASA, is unlikely to be mimicked by adding the
various components of NOSH-ASA together, that is by ASA (o-, m-,
or p-) plus NO plus H2S. This assertion is based on our previous
studies with o-NOSH-ASA (where we showed that, the biological
activity of o-ASAþSNAP (S-Nitroso-N-acetyl-penicillamine which
releases NO)þ ADT-OH (5-(4-hydroxyphenyl)-3H-1, 2-dithiole-3thione, which releases H2S) was not the same as that of the intact
o-NOSH-ASA molecule [14]. Based on recent reports, what appears
more likely is that the released NO and H2S interact to produce a
new species HSNO, which is a highly reactive intermediate [19,20].
From the results presented here there are two important observations that can be made. One, o-NOSH-ASA is the most potent
positional isomer in both HT-29 and HCT 15 colon cancer cell lines.
The order of potency being o-NOSH-ASA4m-NOSH-ASA4
p-NOSH-ASA. Two, the magnitude of the IC50s for each positional
isomer appears to be same in both cell line, no statistical differences. This strongly suggests that the effect of these positional
isomers of NOSH-ASA on cell growth inhibition is independent of
COX status as HT-29 express both COX-1 and COX-2 whereas HCT
15 are COX null [16]. Based on the IC50s determined here, we chose
50 nM for o-NOSH-ASA, 250 nM for m-NOSH-ASA, and 500 nM for
p-NOSH-ASA as our standard IC50 concentrations, and used multiple of these in all our other studies.
3.2. Effects of positional isomers of NOSH-ASA on HT-29 colon cancer
cell kinetics
Two determinants of cell growth or cellular mass are cell renewal and cell death. Therefore, we evaluated the effects of the
positional isomers of NOSH-ASA on cell proliferation and apoptosis. For proliferation, we chose two concentrations of each
compound, their respective IC50 and 2  IC50 for cell growth inhibition. For apoptosis, we evaluated each compound at its IC50 as
a function of treatment time.
3.2.1. Cell proliferation
At 24 h, all positional isomers of NOSH-ASA reduced PCNA
expression in a dose-dependent manner. Ortho, meta and para
NOSH-aspirins qualitatively had similar effects on proliferation.
These results are graphically represented in Fig. 3A. For o-NOSHASA, the proliferation decreased to 53.3 73% at its IC50 (50 nM)
and 18.7 72% at 2 x IC50 (100 nM); the latter is the highest antiproliferative effect amongst the three compounds. m-NOSH-ASA
decreased cell proliferation to 53.2 74% and 20.1 71%, when
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treated at its IC50 (250 nM) and 2  IC50 (500 nM), respectively. For
p-NOSH-ASA, PCNA expression was reduced to 49.7 73% and
21.57 2% at its IC50 (500 nM) and 2  IC50 (1000 nM), respectively,
compared to the untreated control.
3.2.2. Apoptosis
The proportion of cells undergoing apoptosis increased in a
time dependent manner for all positional isomers of NOSH-ASA, as
determined by Annexin V- FITC and propidium iodide staining,
followed by ﬂow cytometry, Fig. 3B. For o-NOSH-ASA at its IC50
(50 nM), the percent of cells in late apoptotic phase increased from
0 in control cells to about 10.7% by 6 h, to 27.5% by 12 h, and to
56.6% by 24 h. For m-NOSH-ASA at its IC50 (250 nM), the percent of
cells undergoing apoptosis increased from 55% at 6 h to 63.3 by
12 h, and 87.3 by 24 h. For p-NOSH-ASA at its IC50 (500 nM), the
percent of cells undergoing apoptosis increased from 25.3% to
71.7% to 90.3% at 6, 12, 24 h respectively. It therefore appears that,
the p-NOSH-ASA isomer caused the most amount of cell death at
all time points and the ortho isomer caused the least.
3.3. Positional isomers of NOSH-ASA inhibit cyclo-oxygenase enzyme
activity
We determined the percent of enzyme inhibition exerted by oNOSH-ASA, m-NOSH-ASA, and p-NOSH-ASA at their respective
IC50s for cell growth inhibition. As shown in Table 2, all three
positional isomers of NOSH-ASA inhibited the enzymatic activities
of COX-1 more than that of COX-2. The extent of COX-1 inhibition
for all three compounds was in the range 40–50% and for COX-2,
about 20–27%. Since we could not determine an IC50 for ASA at
24 h in HT-29 or HCT 15 cells even though we went up to 5 mM
levels, we decided to evaluate the effects of ASA on COX-1 and
COX-2 enzymatic activity at 1 mM based on our previous studies
with ASA and COX inhibition [14]. At this concentration, both COX1 and COX-2 were inhibited to the same extent, 65 75 and 6073
for COX-1 and COX-2, respectively (Table 2). At lower concentrations, ASA is a signiﬁcantly more potent inhibitor of COX-1 relative
to COX-2 [21]. In order to ensure that there were no anomalies
with our assay system, we also evaluated the inhibitory effects of
indomethacin (1 mM), a nonselective COX inhibitor as a reference
compound [22]. Indomethacin inhibited COX-1 and COX-2 by
757 2% and 69 73%, respectively (Table 2).
Differential inhibition of COX-1 versus COX-2 might suggest
adverse gastrointestinal side effects since that would lead to signiﬁcantly lower PG levels within the gastric mucosa. However, we

Fig. 3. Positional isomers of NOSH-aspirin inhibit proliferation and increase cell death. (A) For proliferation, HT-29 cells were treated with o-NOSH-ASA, m-NOSH-ASA and pNOSH-ASA at the concentration corresponding to their IC50s and 2  IC50s for cell growth inhibition, for 24 h, compared to control. PCNA expression was determined by ﬂow
cytometry and expressed as percentage positive cells. Results are mean 7 SEM of three different experiments. *Po 0.05, †P o0.01 compared with untreated cells. (B) Cells
were treated with the positional isomers of NOSH-ASA at their respective IC50 for cell growth inhibition and analyzed at different times for apoptosis by Annexin V- PI
staining and ﬂow cytometry. All the positional isomers of NOSH-aspirin induce apoptosis in a time-dependent manner. *Po 0.05, †Po 0.01 compared with untreated control
cells.
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Table 2
Inhibition of cyclooxygenase enzyme activity by positional isomers of NOSHaspirin.
% Enzyme Inhibition
Treatment

COX-1

COX-2

Aspirin, 1 mM
o-NOSH-aspirin, 50 nM
m-NOSH-aspirin, 250 nM
p-NOSH-aspirin, 500 nM
Indomethacin, 1 mM

657 5
527 4*
45 7 3*
40 7 3*
757 2

607 3
217 2
27 73
227 2
697 3

Pure ovine COX enzymes were treated with o-NOSH-ASA, m-NOSH-ASA, and pNOSH-ASA at their respective IC50 for cell growth inhibition for 15 min at 4 °C after
which o-COX-1 and o-COX-2 enzyme activity were determined. Results are
mean 7SEM of three independent determinations.
*

Po 0.05 compared to COX-2.

have shown that o-NOSH-ASA was devoid of any GI side effects
even though it inhibited PGs within the gastric mucosa [13]. This
observation is most likely due to the released NO and H2S which
have been shown to be cytoprotective within the stomach [7–12].
Recently we also reported that positional isomers of aspirin (oASA, m-ASA, p-ASA) were equally potent in inhibiting colon cancer
cell growth but had differences in the mode by which they inhibited COX-1 and COX-2 activity [23]. o-ASA (conventional aspirin) was shown to be an irreversible inhibitor of COX-1 and COX2, whereas m-ASA and p-ASA were about 30–35% reversible. These
data may also explain the differential IC50s seen in the present
study for the positional isomers of NOSH-ASA. Also, based on the
plausible metabolic pathway suggested (Fig. 6), it appears that
these molecules may not be able to cause irreversible acetylation
of Ser present in the COX active site. Additional studies are needed
to determine the metabolites formed for these NOSH-aspirins.
3.4. Docking results
The binding interactions of o-NOSH-ASA, m-NOSH-ASA, and pNOSH-ASA with COX-1 and COX-2 enzymes were investigated by
conducting molecular modeling studies. The x-ray crystal structures of ovine COX-1 and murine COX-2 were used to determine
the binding modes of NOSH-aspirins [18].
3.4.1. Molecular docking of the positional isomers of NOSH-ASA with
COX-1 enzyme
The binding interactions of o-NOSH-ASA with COX-1 enzyme
shows that it binds in the COX-1 active site in an open U-shaped
conformation (Fig. 4, panel A) and underwent contacts with most
of the residues that line the binding site. The 5-phenyl-3H-1,2dithiole-3-thione substituent ortho to the (nitrooxybutanoyloxy)
benzoate group was in a hydrophobic region consisting of Val349,

Leu352, Phe381, Tyr385, Trp387, Phe518, Ile523 and Gly526. The
1,2-dithiole-3-thione moiety was oriented closer to the catalytic
site at the apex of COX-1 active site and underwent van der Waal's
contact with side chains of Leu352 and Ile523 respectively (π-alkyl
interaction, distance o5 Å). Hydrophobic π-sulfur interactions
were seen with the disulﬁde sulfurs and aromatic rings of Phe381
and Trp387 (distance o5 Å). The 5-phenyl ring attached to 1,2dithiole-3-thione moiety was in van der Waal's contact with side
chains of Val349 and Ala527 (distance o5 Å). The benzoate ring
with (nitrooxy)butanoyloxy substituent was oriented closer to the
entrance of COX-1 active site and was surrounded by Leu93,
Met113, Val116, Arg120, Val349, Leu531, and Tyr355. The benzoate
C¼ O (COO) linked to 5-phenyl ring underwent electrostatic interaction with the guanidine side chain of Arg120
(distance o 3.0 Å) whereas the benzoate aromatic ring underwent
T-shaped π–π interaction with aromatic ring of Tyr355
(distance o 5 Å). Moving the 5-phenyl-3H-1,2-dithiole-3-thione
substituent from ortho to meta-position in m-NOSH-ASA had a
dramatic effect on its binding mode within COX-1 compared to oNOSH-ASA and exhibits an L-shaped conformation (Fig. 4, panel B).
The 1,2-dithiole-3-thione moiety was oriented closer to the entrance of COX-1 active site in a nonpolar region comprised of
Met113, Val116, Tyr355 and Leu359. The sulfur atom (dithiole ring)
underwent π-sulfur and π–π hydrophobic interaction with Tyr355
(distance o 5 Å). In addition, π-sulfur interaction was seen with
Met113 (distance o5 Å). The 5-phenyl ring next to 1,2-dithiole-3thione was in van der Waal's contact with side chains of Val349,
Ile523 and Ala527 (distance o5 Å). The benzoate ring was oriented closer to the apex of COX-1 active site (distance o5 Å). Interestingly, the charged nitrooxy group (ON þ OO  ) underwent
cation-π interaction with aromatic ring of Phe209 (distance o4 Å).
The binding interactions of p-NOSH-ASA shows that it binds in a
closed U-shaped conformation such that the 1,2-dithiole-3-thione
was oriented closer to the apex of COX-1 binding site (Phe381,
Leu384, Tyr385 and Trp387) as seen with the o-NOSH-ASA (Fig. 4,
panel C). The 1,2-dithiole-3-thione underwent π-sulfur interactions with Phe381 and Trp387 (distance o 5.5 Å). The 5-phenyl
ring linked to 1,2-dithiole-3-thione moiety underwent a number
of van der Waal's contact with side chains of Val349, Leu352,
Ile523 and Ala527 (distance o5 Å). Similar to o-NOSH-ASA the
benzoate ring was oriented closer to the entrance of COX-1 active
site and underwent hydrophobic contacts with Met113 and Val116.
The benzoate C¼ O (COO) linked to 5-phenyl ring underwent
hydrogen bonding interaction with Arg120 and Tyr355
(distance o 3 Å). However unlike o-NOSH-ASA, the (nitrooxy)butanoyloxy substituent in p-NOSH-ASA was not in proximity to the
COX-1 entrance. Instead it was closer to Ser530 and Leu531
(distance o 3 Å). Interestingly the nitrooxy group (ON þ OO  ) underwent polar contact with OH of Ser530 (distance ¼ 2.7 Å), the
acetylation site of aspirin [24]. These investigations show that
positional isomers o-, m-, p-NOSH-ASA exhibit different binding

Fig. 4. Docking of positional isomers of NOSH-ASA to the active site of cyclooxygenase-1. Hydrogen atoms are not shown for clarity. Polar and nonpolar interactions are
colored coded and details are provided in text.
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modes in the COX-1 active site. In this regard, the orientation of
5-membered 1,2-dithiole-3-thione for regioisomers o-NOSH-ASA
and p-NOSH-ASA was similar to the methylthiazole substituent
present in meloxicam which suggests that lipophilic, planar
5-membered rings could orient closer to Phe381, Tyr385 and
Trp387 at the apex of COX-1 enzyme [18].
3.4.2. Molecular docking of the positional isomers of NOSH-ASA with
COX-2 enzyme
In the murine COX-2 enzyme, o-NOSH-ASA exhibits a completely different binding mode compared to COX-1 (Fig. 4, panel
D). The (nitrooxy)butanoyloxy substituent was closer to the apex
of COX-2 (Leu384, Tyr385 and Trp387) with the nitrooxy moiety
(ON þ OO  ) undergoing hydrogen bonding interaction with Tyr385
OH (distance ¼ 2.1 Å). The butanoyloxy group was in van der
Waal's contact with side chains of Leu352, Val523 and Ala527
(distance o5 Å). The benzoate aromatic ring underwent π-alkyl
interactions with side chains of Ala527 and Leu531
(distance o5 Å) and the benzoate C ¼ O (COO) formed hydrogen
bond with Arg120 side chain (distance o 2.5 Å). The 5-phenyl-3 H1,2-dithiole-3-thione was oriented closer to the COX-2 entrance in
a region comprised of Pro84, Val89, Tyr115 and Arg120
(distance o5 Å). The 5-phenyl aromatic ring underwent cation-π
interactions with Arg120 and hydrophobic interactions with Val89
and Val116 respectively (distance o5 Å). The sulfur containing 1,2dithiole-3-thione ring was closer to Pro84, Val89 and Tyr115
(distance o5.5 Å). The binding interaction of m-NOSH-ASA shows
an open hair pin conformation (Fig. 4, panel E). Similar to its
binding in COX-1 active site, the 5-phenyl-1,2-dithiole-3-thione
was oriented closer to the COX-2 entrance where 5-phenyl substituent underwent π-alkyl and π-π interactions with Val116 and
Tyr355 respectively (distance o5 Å). The 1,2-dithiole-3-thione
formed π-alkyl and cation-π interactions with Val89 and Arg120
side chains respectively (distance o5 Å). However, unlike its
binding in COX-1, the benzoate with its nitrooxy(butanoyloxy)
substituent was oriented closer to Val349, Ser530 and Leu531
whereas the nitrooxy moiety (ON þ OO  ) underwent hydrogen
bonding interaction with Tyr385 OH (distance¼ 2.2 Å) as seen with
o-NOSH-ASA within COX-2 enzyme (Fig. 4 panel D). Interestingly
the butanoyloxy oxygen (OCO) was forming a hydrogen bonding
interaction with Ser530 (distance¼2.1 Å). The binding interaction of
p-NOSH-ASA which contains a para 5-phenyl-3H-1,2-dithiole-3thione ring, showed an almost linear conformation unlike that seen
with either o-NOSH-ASA or m-NOSH-ASA (Fig. 4, panel F). The nitrooxy (butanoyloxy) substituent was closer to Tyr385 and Trp387.
Interestingly the nitrooxy moiety (ON þ OO  ) underwent hydrogen
bonding interaction with backbone NH of Ala527 (distance¼2.7 Å)
which was not seen for either o-NOSH-ASA or m-NOSH-ASA (Fig. 4
panels D and E) and the benzoate aromatic ring was in van der
Waal's contact with Val349 and Ala527 (distanceo5 Å). Interestingly as seen with m-NOSH-ASA, the butanoyloxy oxygen (OCO)
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was forming a hydrogen bonding interaction with Ser530
(distance¼ 1.8 Å) whereas the benzoate oxygen atom underwent
hydrogen bonding interaction with Arg120 (distance¼2.7 Å). The
entire 5-phenyl-3H-1,2-dithiole-3-thione substituent was oriented
beyond the entrance of COX-2 active site in a region comprised of
Leu93, Val89, Tyr115 and Val116. The 1,2-dithiole-3-thione underwent π-alkyl, π–π and π-sulfur interactions with Val89, Leu93 and
Tyr115 respectively (distanceo5 Å).
Based on these studies it appears that the binding inhibition
and potency of o-NOSH-ASA, m-NOSH-ASA, and p-NOSH-ASA toward COX-1 enzymes was sensitive to regioisomeric placement of
5-phenyl-3H-1,2-dithiole-3-thione substituent. In this regard, the
presence of a bulkier isoleucine (Ile523) in COX-1 active site instead of a smaller valine (Val523) affects the binding orientation
and stability of ligand–enzyme complex of o-, m-, p-NOSH-ASA
with the ortho regioisomer (o-NOSH-ASA) exhibiting better stability (CDOCKER energy ¼  15.05 kcal/mol) compared to meta (mNOSH-ASA) and para (p-NOSH-ASA) regioisomers (CDOCKER energies¼  12.76 and  4.24 kcal/mol respectively). In contrast, the
presence of a smaller valine (Val523) in COX-2 active site makes it
slightly larger. This factor appears to accommodate the regioisomeric NOSH-aspirin derivatives (o-, m-, p-NOSH-ASA) such
that they all exhibit a similar binding mode within COX-2 active
site where the 5-phenyl-3H-1,2-dithiole-3-thione substituent is
oriented closer to COX-2 entrance despite their regioisomeric
differences. The ligand–enzyme complex of o-NOSH-ASA with
COX-2 exhibited better stability (CDOCKER energy ¼ 24.0 kcal/
mol) compared to m-NOSH-ASA (CDOCKER energy ¼  7.34 kcal/
mol) and p-NOSH-ASA (CDOCKER energy ¼  22.16 kcal/mol). The
in vitro COX inhibition studies indicate that NOSH-aspirins exhibit
better activity toward COX-1 enzyme which is supported by the
modeling studies where it is seen that the lipophilic 1,2-dithiole3-thione substituent is generally buried in a solvent exposed polar
environment beyond COX-2 entrance which was not seen with the
COX-1 binding modes.
It should be noted that in vivo, the positional isomers of NOSHASA may form a number of metabolites as suggested in Fig. 5.
Among them, proposed metabolites 1–5 are capable of exhibiting
COX inhibition on their own. Furthermore, depending on the dose,
frequency and routes of administration, a fraction of intact NOSHaspirin derivatives can interact and inhibit the COX enzymes (Fig.6).
In summary, in the present study, we demonstrated that all
three positional isomers of NOSH aspirin inhibit the growth of HT29 and HCT-15 colon cancer cell lines with different IC50s, suggesting an important role for positional isomerism in modulating
the potential anti-cancer properties of these compounds. However, since the IC50s in each cell line were about same nano-molar
range, we can conclude that this effect is independent COX status.
All three positional isomers of NOSH-aspirin, inhibited proliferation
of HT-29 cells and induced apoptosis, two determinants of cell
mass. All three compounds also preferentially inhibited COX-1

Fig. 5. Docking of positional isomers of NOSH-ASA to the active site of cyclooxygenase-2. Hydrogen atoms are not shown for clarity. Polar and nonpolar interactions are
colored coded and details are provided in text.
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Fig. 6. The potential in vivo metabolites of o-, m-, p-NOSH-ASA derivatives.

enzyme activity. Our results also demonstrate that positional isomerism markedly affects the anti-neoplastic potential of NOSH-ASA
in colon cancer. In particular, o-NOSH-ASA appears to be 5-fold
more potent than m-NOSH-ASA and 10-fold more potent than pNOSH-ASA. We are currently evaluating the many potential molecular targets of these novel compounds in various models of cancer.
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